# Alnara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alnara-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.alnara.com
- Total disclosed funding: $55M
- Latest round: Series B (Jan 28, 2010)
- Investors on record: 5

## About

Alnara Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for unmet medical needs, particularly in the field of metabolic diseases.Founded in 2008 and headquartered in Cambridge, US, Alnara Therapeutics is engaged in the development of therapeutic solutions. In July 2010, the company was acquired by Eli Lilly and Company Limited for USD 180 mn, with potential additional payments of USD 200 mn contingent on performance metrics.Alnara.com specializes in the sale and leasing of domain names, offering a streamlined platform for users to acquire digital real estate. The company's core product is the domain name alnara.com, available for a purchase price of USD 9,995 or through a Lease to Own option priced at USD 480 monthly. This service targets a diverse clientele, including entrepreneurs, small businesses, and larger corporations looking to establish or enhance their online presence. The transaction process is designed to be user-friendly, ensuring that customers can navigate through secure payments and local currency options at checkout. Alnara.com caters to a global market, providing domain name services to clients in North America, Europe, and Asia, addressing the increasing demand for unique and memorable online identities.The revenue model of Alnara.com is driven primarily by the direct sale and leasing of domain names, with transactions occurring through clear pricing structures. Customers can choose between one-time payments for outright purchase or opt for a monthly leasing plan, allowing for flexibility in financial commitment. Each transaction is supported by a commitment to secure payments and hassle-free transfers, enhancing customer confidence and satisfaction. The primary offering is the domain name alnara.com, and the pricing structure reflects a premium market position, catering to businesses looking for high-value digital assets. This approach not only facilitates direct-to-consumer sales but also opens avenues for business-to-business transactions, where companies might engage in leasing arrangements for longer-term digital strategies.The company is expected to leverage recent funding to support its growth strategies, focusing on expanding its product offerings and enhancing service delivery. In July 2010, the definitive acquisition agreement with Eli Lilly & Co. positions Alnara Therapeutics to potentially develop new therapeutic products that address metabolic diseases. The firm aims to strengthen its presence in both existing and emerging markets, ensuring a broader reach for its solutions. Future product launches are anticipated, although specific details and dates have yet to be disclosed.

## Funding rounds

- Series B, Jan 28, 2010, $35M — Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures, MPM BioImpact, Longwood Fund
- Series A, Oct 30, 2008, $20M — Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B